The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:


	June 30,
	2026	2025
Common stock options granted and outstanding	4,932,374	3,888,145
Restricted stock units granted and outstanding	425,867	29,740
Common stock warrants outstanding	163,769	164,252
ESPP shares pending purchase	12,019	4,791
Total	5,534,029	4,086,928